Chitinase 3-Like 2

• Published in: American journal of clinical pathology Vol. 158; no. 4; pp. 521 - 529
• Main Authors: Nimbalkar, Vidya P, Kruthika, Banavathy S, Sravya, Palavalasa, Rao, Shilpa, Sugur, Harsha S, Chickabasaviah, Yasha T, Somanna, Sampath, Arivazhagan, Arimappamagan, Kondaiah, Paturu, Santosh, Vani
• Format: Journal Article
• Language: English
• Published: US Oxford University Press 06.10.2022
• Subjects: CHI3L2; PBZ; Prognosis; Tumor recurrence; Glioblastoma
• ISSN: 0002-9173; 1943-7722
• DOI: 10.1093/ajcp/aqac082

Abstract Objectives We aimed to evaluate the expression pattern of chitinase 3-like 2 (CHI3L2) in the tumor core and peritumoral brain zone (PBZ) of newly diagnosed glioblastoma (GBM) in recurrent tumors and its association with patient prognosis. Methods The study was conducted on three sample sets derived from different patient cohorts. Messenger RNA (mRNA) expression of CHI3L2 in the tumor core and PBZ (n = 34) compared with control (n = 20) tissues was studied by quantitative polymerase chain reaction in sample set 1. Sample set 2 included 19 paired, primary-recurrent GBM tissues. Sample set 3 comprised 82 GBM tissues of patients with treatment and follow-up information. Immunohistochemistry (IHC) was performed on all three sample sets. Results mRNA expression of CHI3L2 was significantly higher in the tumor core and PBZ compared with control (P < .0001). By IHC, CHI3L2 showed strong cytoplasmic staining in tumor cells. Recurrent tumors had a higher expression of CHI3L2 compared with primary tumors (P = .007). Survival analysis showed CHI3L2 expression was associated with shorter overall survival (P = .034) and progression-free survival (P = .010), which was in line with The Cancer Genome Atlas cohort (P = .043). Conclusions High expression of CHI3L2 in the tumor core and PBZ, as well as its association with tumor recurrence and poor patient prognosis, suggests it might be contributing to tumor spread and recurrence.